cbdMD Statistics
Total Valuation
cbdMD has a market cap or net worth of $7.45 million. The enterprise value is $4.66 million.
Important Dates
The last earnings date was Tuesday, February 17, 2026, after market close.
| Earnings Date | Feb 17, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
cbdMD has 10.50 million shares outstanding. The number of shares has increased by 941.35% in one year.
| Current Share Class | 10.50M |
| Shares Outstanding | 10.50M |
| Shares Change (YoY) | +941.35% |
| Shares Change (QoQ) | +0.47% |
| Owned by Insiders (%) | 2.71% |
| Owned by Institutions (%) | 15.54% |
| Float | 10.21M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.39 |
| Forward PS | 0.47 |
| PB Ratio | 0.79 |
| P/TBV Ratio | 1.05 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.24 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.94, with a Debt / Equity ratio of 0.07.
| Current Ratio | 2.94 |
| Quick Ratio | 1.62 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | 1.84 |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -43.36% and return on invested capital (ROIC) is -22.70%.
| Return on Equity (ROE) | -43.36% |
| Return on Assets (ROA) | -12.66% |
| Return on Invested Capital (ROIC) | -22.70% |
| Return on Capital Employed (ROCE) | -26.23% |
| Weighted Average Cost of Capital (WACC) | 14.67% |
| Revenue Per Employee | $454,617 |
| Profits Per Employee | -$88,443 |
| Employee Count | 42 |
| Asset Turnover | 1.64 |
| Inventory Turnover | 2.68 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -66.88% in the last 52 weeks. The beta is 2.11, so cbdMD's price volatility has been higher than the market average.
| Beta (5Y) | 2.11 |
| 52-Week Price Change | -66.88% |
| 50-Day Moving Average | 0.89 |
| 200-Day Moving Average | 0.90 |
| Relative Strength Index (RSI) | 42.26 |
| Average Volume (20 Days) | 614,264 |
Short Selling Information
The latest short interest is 229,562, so 2.19% of the outstanding shares have been sold short.
| Short Interest | 229,562 |
| Short Previous Month | 2.41M |
| Short % of Shares Out | 2.19% |
| Short % of Float | 2.25% |
| Short Ratio (days to cover) | 0.19 |
Income Statement
In the last 12 months, cbdMD had revenue of $19.09 million and -$3.71 million in losses. Loss per share was -$0.61.
| Revenue | 19.09M |
| Gross Profit | 11.57M |
| Operating Income | -2.36M |
| Pretax Income | -2.34M |
| Net Income | -3.71M |
| EBITDA | -1.29M |
| EBIT | -2.36M |
| Loss Per Share | -$0.61 |
Full Income StatementBalance Sheet
The company has $3.39 million in cash and $593,026 in debt, with a net cash position of $2.79 million or $0.27 per share.
| Cash & Cash Equivalents | 3.39M |
| Total Debt | 593,026 |
| Net Cash | 2.79M |
| Net Cash Per Share | $0.27 |
| Equity (Book Value) | 9.01M |
| Book Value Per Share | 0.89 |
| Working Capital | 5.39M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$1.95 million and capital expenditures -$184,587, giving a free cash flow of -$2.13 million.
| Operating Cash Flow | -1.95M |
| Capital Expenditures | -184,587 |
| Free Cash Flow | -2.13M |
| FCF Per Share | -$0.20 |
Full Cash Flow StatementMargins
Gross margin is 60.59%, with operating and profit margins of -12.37% and -12.25%.
| Gross Margin | 60.59% |
| Operating Margin | -12.37% |
| Pretax Margin | -12.25% |
| Profit Margin | -12.25% |
| EBITDA Margin | -6.75% |
| EBIT Margin | -12.37% |
| FCF Margin | n/a |
Dividends & Yields
cbdMD does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -941.35% |
| Shareholder Yield | -941.35% |
| Earnings Yield | -49.85% |
| FCF Yield | -28.60% |
Analyst Forecast
The average price target for cbdMD is $2.00, which is 181.69% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $2.00 |
| Price Target Difference | 181.69% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 7, 2025. It was a reverse split with a ratio of 1:8.
| Last Split Date | May 7, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:8 |
Scores
cbdMD has an Altman Z-Score of -18.51 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -18.51 |
| Piotroski F-Score | 3 |
